(Reuters) - Shares of biotechs racing to make coronavirus vaccines, including Moderna Inc (MRNA.O), fell about 10% on Wednesday, as investor concerns grew about the prospects of the experimental products that are still in early stages of development.

Shares of the company fell as investors questioned the widely accepted timeline of 12 to 18 months for developing a vaccine for the new coronavirus, and also worried about a lack of granular data on the vaccines, analysts said.

Wall Street was also concerned about a lack of data on the experimental vaccines under development, said Roth Capital Partners analyst Yasmeen Rahimi.